## Note
nid: 1520901347807
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#B&B::15_Neuro::07_Other::06_Headaches, #AK_Step1_v11::#FirstAid::12_Neuro_&_Special_Senses::06_Pharm::07_Triptans, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#Physeo::11_Pathology::05_Neuropathology_Pathology::07_Headaches, #AK_Step1_v11::#SketchyPharm::06_Neuro/Psych::FA-Neuro, #AK_Step1_v11::$AnKingUpdates::$Errata::v11, #AK_Step1_v11::^Other::^EXPN::BGadd, #AK_Step1_v11::^Other::^EXPN::BGnonessentials, #AK_Step1_v11::^Other::^EXPN::Uworld, #AK_Step1_v11::^Other::^HighYield::4-LowerYield, #AK_Step1_v11::^Systems::Neuro::Pharmacology
markdown: false

### Text
{{c3::<b>Dihydroergotamine</b>}} is not frequently used for
migraine treatment due to its significant side effect profile,
including {{c1::gangrene}} and {{c2::vasospastic (prinzmetal)
angina}}

### Extra
Dihydroergotamine constricts vascular smooth muscle via stimulation of both A1 adrenergic receptors (partial agonist) and serotonergic receptors (5HT1b/d)

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
#REF!

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources


### One by one

